Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AngioDynamics buys Oncobionic

This article was originally published in The Gray Sheet

Executive Summary

Privately held irreversible electroporation (IRE) soft tissue ablation technology developer Oncobionic is acquired by AngioDynamics. The deal is valued at up to $25 mil. - including $5 mil. up-front and up to $20 mil. in milestone payments. Announced Oct. 17, the agreement builds on the firms' 2004 distribution and option pact for the IRE device. Trials for liver and prostate cancer are slated to begin in mid-2007, followed by a market launch in 2008. A 510(k) application is pending at FDA for use in general tissue ablation. IRE uses needles, an electrical field and image guidance to disrupt targeted cell membranes without causing thermal damage, firm says...

You may also be interested in...

AngioDynamics Will Break Into Oncology Biz With $220 Mil. Rita Purchase

AngioDynamics will gain immediate access to the targeted tumor ablation market and will fill out its vascular access business in a $220 mil. acquisition of Rita Medical

Butterfly Network’s CEO Sees Blank Check Deal As Path To ‘Democratize’ Portable Imaging Platform

Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.

Regenerative Medicine Comes Of Age – In The Age Of COVID-19

Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts